3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Unknown
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Pancreatic Neoplasms
4
Sarcoma
2
Hypoxia
2
Solid Tumors
1
Solid Tumor
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neuroendocrine Tumors
1
Neuroectodermal Tumors, Primitive
1
Neoplasms
1
Neoplasm Metastasis
1
Liver Neoplasms
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Kidney Neoplasms
1
Glioma
1
Glioblastoma
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Interventions
Gemcitabine
9
Paclitaxel
8
Carboplatin
7
atezolizumab
6
Sunitinib
5
navitoclax
4
Topotecan
4
Irinotecan
4
Docetaxel
4
Bevacizumab
4
pazopanib
3
liposomal doxorubicin
3
cobimetinib
3
Nivolumab
3
Erlotinib Hydrochloride
3
zolbetuximab
2
tumor necrosis factor-alpha, CNGRC fusion protein, human
2
temsirolimus
2
selicrelumab
2
plocabulin
2
envafolimab
2
darinaparsin
2
brigimadlin
2
adavosertib
2
Tablets
2
Sorafenib
2
Rifampin
2
RG7388
2
Panitumumab
2
NVP-BKM120
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Solid Tumors
×
TH 302
×
Clear all
NCT01485042
2017-09-01
PATH
Duke University
Phase 1
Completed
50 enrolled